Inventiva S.A. (IVA)
NASDAQ: IVA · IEX Real-Time Price · USD
2.600
+0.050 (1.96%)
Jul 19, 2024, 4:00 PM EDT - Market closed
Inventiva Revenue
In the year 2023, Inventiva had annual revenue of $25.74M with 28.59% growth.
Revenue (ttm)
$25.74M
Revenue Growth
+28.59%
P/S Ratio
5.29
Revenue / Employee
$209,241
Employees
123
Market Cap
136.16M USD
Revenue Chart
* The company reports in EUR currency but revenue data is shown in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 25.74M | 5.72M | 28.59% |
Dec 31, 2022 | 20.01M | 10.35M | 107.19% |
Dec 31, 2021 | 9.66M | 3.24M | 50.51% |
Dec 31, 2020 | 6.42M | -6.27M | -49.41% |
Dec 31, 2019 | 12.69M | 4.20M | 49.58% |
Dec 31, 2018 | 8.48M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Amylyx Pharmaceuticals | 398.00M |
Harvard Bioscience | 106.79M |
DIH Holdings US | 64.47M |
Electromed | 53.50M |
Veru Inc. | 13.48M |
Cellectis | 12.13M |
IVA News
- 2 days ago - Half-Year Review of Inventiva's Liquidity Contract with Kepler Cheuvreux - GlobeNewsWire
- 4 days ago - Inventiva announces a €20.1 million issuance of royalty certificates - GlobeNewsWire
- 16 days ago - Inventiva provides an update on its NATiV3 clinical program evaluating lanifibranor in patients with MASH/NASH and its financial position - GlobeNewsWire
- 4 weeks ago - Results of the votes of the Combined Shareholders' General Meeting of June 20, 2024 - GlobeNewsWire
- 7 weeks ago - Combined General Meeting of June 20, 2024 - Availability of the preparatory documents - GlobeNewsWire
- 2 months ago - Inventiva announces two scientific presentations at the EASL International Liver Congress™ 2024 - GlobeNewsWire
- 2 months ago - Inventiva reports 2024 First Quarter Financial Information¹ and provides a corporate update - GlobeNewsWire
- 2 months ago - Inventiva announces the positive recommendation of the fourth DMC of the NATiV3 Phase III clinical trial with lanifibranor in patients with MASH/NASH - GlobeNewsWire